VL-0395

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 532878

CAS#: 620167-11-5

Description: VL-0395 is a CCK1 receptor antagonist.


Price and Availability

Size
Price

Size
Price

Size
Price

VL-0395 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 532878
Name: VL-0395
CAS#: 620167-11-5
Chemical Formula: C26H23N5O4
Exact Mass: 469.175
Molecular Weight: 469.5
Elemental Analysis: C, 66.51; H, 4.94; N, 14.92; O, 13.63


Synonym: VL-0395, VL 0395, VL0395

IUPAC/Chemical Name: 3-[[3-[(5-carbamimidoyl1H-indole-2-carbonyl)amino]benzoyl]amino]-3-phenylpropanoic acid

InChi Key: RVWSCZNGPOUASU-UHFFFAOYSA-N

InChi Code: InChI=1S/C26H23N5O4/c27-24(28)16-9-10-20-18(11-16)13-22(30-20)26(35)29-19-8-4-7-17(12-19)25(34)31-21(14-23(32)33)15-5-2-1-3-6-15/h1-13,21,30H,14H2,(H3,27,28)(H,29,35)(H,31,34)(H,32,33)

SMILES Code: O=C(O)CC(NC(C1=CC=CC(NC(C(N2)=CC3=C2C=CC(C(N)=N)=C3)=O)=C1)=O)C4=CC=CC=C4


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Pavan MV, Lassiani L, Berti F, Stefancich G, Ciogli A, Gasparrini F, Mennuni L, Ferrari F, Escrieut C, Marco E, Makovec F, Fourmy D, Varnavas A. New anthranilic acid based antagonists with high affinity and selectivity for the human cholecystokinin receptor 1 (hCCK1-R). J Med Chem. 2011 Aug 25;54(16):5769-85. doi: 10.1021/jm200438b. Epub 2011 Jul 20. PubMed PMID: 21728335.

2: Lassiani L, Pavan MV, Berti F, Kokotos G, Markidis T, Mennuni L, Makovec F, Varnavas A. Anthranilic acid based CCK1 receptor antagonists: blocking the receptor with the same 'words' of the endogenous ligand. Bioorg Med Chem. 2009 Mar 15;17(6):2336-50. doi: 10.1016/j.bmc.2009.02.012. Epub 2009 Feb 14. PubMed PMID: 19261479.

3: Varnavas A, Lassiani L, Valenta V, Ciogli A, Gasparrini F, Mennuni L, Makovec F. N-terminal anthranoyl-phenylalanine derivatives as CCK1 receptor antagonists: the final approach. Med Chem. 2005 Sep;1(5):501-17. PubMed PMID: 16787335.

4: De Luca S, Saviano M, Lassiani L, Yannakopoulou K, Stefanidou P, Aloj L, Morelli G, Varnavas A. Anthranilic acid based CCK1 receptor antagonists and CCK-8 have a common step in their "receptor desmodynamic processes". J Med Chem. 2006 Apr 20;49(8):2456-62. PubMed PMID: 16610788.

5: Varnavas A, Lassiani L, Valenta V, Mennuni L, Makovec F, Hadjipavlou-Litina D. Anthranilic acid based CCK1 receptor antagonists: preliminary investigation on their second "touch point". Eur J Med Chem. 2005 Jun;40(6):563-81. PubMed PMID: 15922840.

6: Varnavas A, Lassiani L, Valenta V, Berti F, Tontini A, Mennuni L, Makovec F. Anthranilic acid based CCK1 antagonists: the 2-indole moiety may represent a "needle" according to the recent homonymous concept. Eur J Med Chem. 2004 Jan;39(1):85-97. PubMed PMID: 14987837.

7: Varnavas A, Lassiani L, Valenta V, Berti F, Mennuni L, Makovec F. Anthranilic acid derivatives: a new class of non-peptide CCK1 receptor antagonists. Bioorg Med Chem. 2003 Mar 6;11(5):741-51. PubMed PMID: 12538004.